In lung cancer, FRMD6 promoted the tumor growth and invasion via mTOR pathway, while FRMD6, as a tumor suppressor inhibited the carcinogenesis and progression of prostate cancer and glioma [48–50]. Here, MTOR is linked to prostate carcinoma.